• The in vivo biological activity of the

  2021-12-13

  

  The in vivo biological activity of the four novel analogues was then systematically assessed in three animal models including normal control, high fat fed and ob/ob mice. As expected from earlier in vitro studies, all four glucagon receptor antagonists had minor effects on glucose or insulin concent

• The observed increase in macroscopic conductance could be

  2021-12-13

  

  The observed increase in macroscopic conductance could be due to a left shift in the open state probability vs. voltage curve for the high-activity state causing an increase in the open state probability at all potentials. However, an increase of the apparent single channel conductance cannot be ent

• br Therapeutic approaches exploiting Cx function Due to thei

  2021-12-13

  

  Therapeutic approaches exploiting Cx43 function Due to their potential role in cancer metastasis, attempts have been made to alter connexin function to inhibit cancer growth. Therapeutic approaches include Cx43 peptide mimetics, Cx43 inhibitors, chemical agents capable of enhancing Cx43 function,

• GLP is released in response to ingestion of nutrients

  2021-12-13

  

  GLP-1 is released in response to ingestion of nutrients including carbohydrates, protein, and fat. Recent studies aimed at identifying the receptors involved in nutrient stimulated GLP-1 secretion have identified free fatty hyPerFUsion™ high-fidelity PCR Kit receptor 4 (FFA4/GPR120) as a potential

• However the clinical development of was terminated in

  2021-12-13

  

  However, the clinical development of was terminated in 2013 due to the concerns over liver toxicity, raising important questions regarding the long-term safety and viability of targeting GPR40 and, more specifically, about our understanding of the pharmacobiology and signaling spectrum of this rece

• So what makes a FFAR agonist different and

  2021-12-13

  

  So what makes a FFAR1 agonist different and interesting? As shown in the , the cellular mechanism is different from those of present insulin-releasing pharmacotherapies—namely the secretion initiators (sulphonylureas and meglitinides) and the incretin-based secretion potentiators (glucagon-like pept

• We detected the FFAR protein with a molecular mass of

  2021-12-13

  

  We detected the FFAR2 protein with a molecular mass of about 50 kDa, which is comparable to the main band detected in pigs (Li et al., 2014) but different from the calculated size based on the sequence (Wang et al., 2009). The size difference can be explained, at least in part, by glycosylation site

• A second H R antagonist with benzamide based structure

  2021-12-13

  

  A second H3R antagonist with benzamide-based structure from Johnson & Johnson is JNJ-31001074, known as Bavisant and under chemical IUPAC name of (4-cyclopropylpiperazin-1-yl)-[4-(morpholin-4-ylmethyl)phenyl]methanone. It is a compound with molecular weight 329.44, HBA four, and MLogP 1.52 encompass

• The mast cell has long been recognized

  2021-12-13

  

  The mast cell has long been recognized as central to the mediation of allergic responses not least because it is the principal repository of histamine in the body. Following activation by allergens, the mast cell can release histamine as well as generate a host of additional mediators such as cystei

• To identify structurally novel autophagy

  2021-12-10

  

  To identify structurally novel autophagy inhibitors, a medium throughput screen of our in-house library of approximately 160,000 compounds was performed. In the screening assay, MCF7 ifenprodil australia stably transfected with eGFP-tagged light chain 3 (LC3), were employed, which can be detected b

• Reports of hyperlocomotion after administration

  2021-12-10

  

  Reports of hyperlocomotion after administration of ALX-5407 [27] coupled with the lack of hyperlocomotion after administration of SSR504734, a non-sarcosine, long-residence time, competitive inhibitor [19], suggested that the GlyT1 inhibitor chemotype may impact OP. Furthermore, a compound with a co

• An alternative approach to improving pharmacokinetic profile

  2021-12-10

  

  An alternative approach to improving pharmacokinetic profile while retaining high GlyT1 potency was also pursued. Libraries were prepared in which potency enhancing piperidine C4 substituents were combined with clearance lowering truncated alkyl sulfonamides. The result was the discovery of (). Unl

• br The glycine transporter GlyT was originally

  2021-12-10

  

  The glycine transporter 1 (GlyT1) was originally identified as a member of the solute carrier family 6 of sodium- and chloride-dependent neurotransmitter transporters . GlyT1 is expressed in the central nervous system and in peripheral tissues; mainly in erythroid cells, from erythroblasts in the

• In fact changes in mitochondrial dynamics directly affects

  2021-12-10

  

  In fact, changes in mitochondrial dynamics directly affects many things including cellular metabolism [127], mitochondrial mass and turnover [128], mitochondrial transport, and calcium buffering [129]. Nigrostriatal DA neurons seem to have a preferential susceptibility to loss of Mfn2 when compared

• GW 6471 Polymerisation of HbS initiates the clinical complic

  2021-12-10

  

  Polymerisation of HbS initiates the clinical complications of SCD (Bunn and Forget, 1986). The resulting sequelae are multiple and diverse, and their individual impact on pathogenesis is difficult to elucidate. Early changes include altered red cell membrane permeability (Gibson and Ellory, 2002, Le

16581 records 567/1106 page Previous Next First page 上5页 566567568569570 下5页 Last page